These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33898773)

  • 1. Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator.
    Yang J; Vedam S; Lee B; Castillo P; Sobremonte A; Hughes N; Mohammedsaid M; Wang J; Choi S
    Phys Imaging Radiat Oncol; 2021 Jan; 17():20-24. PubMed ID: 33898773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer.
    Fink CA; Buchele C; Baumann L; Liermann J; Hoegen P; Ristau J; Regnery S; Sandrini E; König L; Rippke C; Bonekamp D; Schlemmer HP; Debus J; Koerber SA; Klüter S; Hörner-Rieber J
    Front Oncol; 2024; 14():1308406. PubMed ID: 38425342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes.
    Brennan VS; Burleson S; Kostrzewa C; Godoy Scripes P; Subashi E; Zhang Z; Tyagi N; Zelefsky MJ
    Radiother Oncol; 2023 Feb; 179():109441. PubMed ID: 36549340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
    Schaule J; Chamberlain M; Wilke L; Baumgartl M; Krayenbühl J; Zamburlini M; Mayinger M; Andratschke N; Tanadini-Lang S; Guckenberger M
    Radiat Oncol; 2021 Sep; 16(1):189. PubMed ID: 34565439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
    Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
    Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors.
    Padgett KR; Simpson GN; Llorente R; Samuels MA; Dogan N
    Cureus; 2018 Apr; 10(4):e2423. PubMed ID: 29872603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study.
    Willigenburg T; Beld E; Hes J; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN
    Phys Imaging Radiat Oncol; 2020 Jul; 15():60-65. PubMed ID: 33458327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
    Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
    Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art Cone-Beam Computed Tomography (CBCT).
    Rechner LA; Felter M; Bekke S; Biancardo S; Rønjom MF; Pedersen M; Sjöström D; Chen IM; Sibolt P
    Cureus; 2024 Sep; 16(9):e68386. PubMed ID: 39355470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results.
    Sandoval ML; Youssef I; Latifi K; Grass GD; Torres-Roca J; Rosenberg S; Yamoah K; Johnstone PA
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of daily plan adaptation on accumulated doses in ultra-hypofractionated magnetic resonance-guided radiation therapy of prostate cancer.
    Xiong Y; Rabe M; Rippke C; Kawula M; Nierer L; Klüter S; Belka C; Niyazi M; Hörner-Rieber J; Corradini S; Landry G; Kurz C
    Phys Imaging Radiat Oncol; 2024 Jan; 29():100562. PubMed ID: 38463219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions.
    Bryant JM; Weygand J; Keit E; Cruz-Chamorro R; Sandoval ML; Oraiqat IM; Andreozzi J; Redler G; Latifi K; Feygelman V; Rosenberg SA
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer.
    Künzel LA; Nachbar M; Hagmüller M; Gani C; Boeke S; Zips D; Thorwarth D
    Radiother Oncol; 2021 Jun; 159():197-201. PubMed ID: 33812912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer.
    Tetar SU; Bruynzeel AME; Lagerwaard FJ; Slotman BJ; Bohoudi O; Palacios MA
    Phys Imaging Radiat Oncol; 2019 Jan; 9():69-76. PubMed ID: 33458428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
    Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
    JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy.
    Willigenburg T; van der Velden JM; Zachiu C; Teunissen FR; Lagendijk JJW; Raaymakers BW; de Boer JCJ; van der Voort van Zyp JRN
    Radiother Oncol; 2022 Jun; 171():182-188. PubMed ID: 35489444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac.
    Dang J; Kong V; Li W; Navarro I; Winter JD; Malkov V; Berlin A; Catton C; Padayachee J; Raman S; Warde P; Chung P
    Tech Innov Patient Support Radiat Oncol; 2022 Sep; 23():41-46. PubMed ID: 36105770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric Feasibility of Utilizing the ViewRay Magnetic Resonance Guided Linac System for Image-guided Spine Stereotactic Body Radiation Therapy.
    Redler G; Stevens T; Cammin J; Malin M; Green O; Mutic S; Pitroda S; Aydogan B
    Cureus; 2019 Dec; 11(12):e6364. PubMed ID: 31938646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer.
    Bohoudi O; Bruynzeel AME; Tetar S; Slotman BJ; Palacios MA; Lagerwaard FJ
    Radiother Oncol; 2021 Apr; 157():197-202. PubMed ID: 33545251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.